PL1968592T3 - Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych - Google Patents

Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych

Info

Publication number
PL1968592T3
PL1968592T3 PL06795019T PL06795019T PL1968592T3 PL 1968592 T3 PL1968592 T3 PL 1968592T3 PL 06795019 T PL06795019 T PL 06795019T PL 06795019 T PL06795019 T PL 06795019T PL 1968592 T3 PL1968592 T3 PL 1968592T3
Authority
PL
Poland
Prior art keywords
formulations
jorumycin
renieramycin
safracin
saframycin
Prior art date
Application number
PL06795019T
Other languages
English (en)
Inventor
Salve Pilar Calvo
Barreira María Tobio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PL1968592T3 publication Critical patent/PL1968592T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL06795019T 2005-10-31 2006-10-30 Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych PL1968592T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0522082.7A GB0522082D0 (en) 2005-10-31 2005-10-31 Formulations
EP06795019A EP1968592B1 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds and a disaccharide for treating proliferative diseases
PCT/GB2006/050362 WO2007052076A2 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
PL1968592T3 true PL1968592T3 (pl) 2012-08-31

Family

ID=35515969

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06795019T PL1968592T3 (pl) 2005-10-31 2006-10-30 Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych

Country Status (23)

Country Link
US (1) US9192568B2 (pl)
EP (1) EP1968592B1 (pl)
JP (1) JP5197373B2 (pl)
KR (1) KR101434230B1 (pl)
CN (1) CN101300011B (pl)
AT (1) ATE549023T1 (pl)
AU (1) AU2006310260C1 (pl)
CA (1) CA2625096C (pl)
DK (1) DK1968592T3 (pl)
ES (1) ES2383967T3 (pl)
GB (1) GB0522082D0 (pl)
HR (1) HRP20120478T1 (pl)
IL (1) IL190774A (pl)
NO (1) NO341057B1 (pl)
NZ (1) NZ567291A (pl)
PL (1) PL1968592T3 (pl)
PT (1) PT1968592E (pl)
RS (1) RS52312B (pl)
RU (1) RU2429845C2 (pl)
SI (1) SI1968592T1 (pl)
UA (1) UA97629C2 (pl)
WO (1) WO2007052076A2 (pl)
ZA (1) ZA200803420B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
CA2724206A1 (en) * 2008-05-16 2009-11-19 Pharma Mar S.A. Multiple myeloma treatments
CA2724325A1 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CA3024230C (en) 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
WO2019018539A1 (en) * 2017-07-19 2019-01-24 California Institute Of Technology PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
US20240197726A1 (en) * 2021-03-03 2024-06-20 The University Of Tokyo Novel tetrahydroisoquinoline alkaloid compound containing macrocycle

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) * 1996-02-13 1997-08-14 Basf Ag Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
CN1157189C (zh) 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EP1339713A2 (en) * 2000-11-03 2003-09-03 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
EP1365808B1 (en) 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
EE200300429A (et) * 2001-03-06 2003-12-15 Bristol-Myers Squibb Company Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7251892B2 (en) * 2003-07-09 2007-08-07 Temper Corporation Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
DK1827500T3 (da) * 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
WO2006066183A2 (en) * 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
UA97629C2 (ru) 2012-03-12
WO2007052076A2 (en) 2007-05-10
AU2006310260A1 (en) 2007-05-10
DK1968592T3 (da) 2012-07-02
SI1968592T1 (sl) 2012-10-30
EP1968592A2 (en) 2008-09-17
NO341057B1 (no) 2017-08-14
IL190774A0 (en) 2008-11-03
JP2009513618A (ja) 2009-04-02
US20090076016A1 (en) 2009-03-19
JP5197373B2 (ja) 2013-05-15
AU2006310260B2 (en) 2012-08-09
CA2625096A1 (en) 2007-05-10
RU2429845C2 (ru) 2011-09-27
CN101300011A (zh) 2008-11-05
RS52312B (sr) 2012-12-31
KR20080064959A (ko) 2008-07-10
ES2383967T3 (es) 2012-06-27
NO20082425L (no) 2008-07-25
ATE549023T1 (de) 2012-03-15
NZ567291A (en) 2011-04-29
HK1122743A1 (en) 2009-07-17
HRP20120478T1 (hr) 2012-07-31
AU2006310260C1 (en) 2013-09-19
CA2625096C (en) 2015-11-24
KR101434230B1 (ko) 2014-08-26
RU2008121716A (ru) 2009-12-10
CN101300011B (zh) 2011-12-28
WO2007052076A3 (en) 2008-03-20
EP1968592B1 (en) 2012-03-14
US9192568B2 (en) 2015-11-24
PT1968592E (pt) 2012-06-18
IL190774A (en) 2013-11-28
GB0522082D0 (en) 2005-12-07
ZA200803420B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
JO2464B1 (en) Formulas contain actinacidine and binary sugars
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
WO2007061874A3 (en) Methods and compositions for use in treating cancer
MY152283A (en) Polo-like kinase inhibitirs
UA96301C2 (ru) Замещенный фенилтиотрифторид и другие подобные фторирующие агенты
TNSN08069A1 (en) Amorphous solid dispersions of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5,-dihydro-4h-pyridazino[4,5 b] indole -1- acetamide
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
WO2008027600A3 (en) Imatinib compositions
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
TW200640926A (en) Pyrazolopyrimidines
IL200000A (en) Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds
PL2059503T3 (pl) Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodne
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2007033374A3 (en) Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
GB0515025D0 (en) Organic compounds
TW200738236A (en) Certain chemical entities, compositions, and methods
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
IL184940A0 (en) Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
WO2007059113A3 (en) Certain chemical entities, compositions, and methods